Researchers uncover allergy-cancer connection
While many are stocking up on allergy medicine in preparation for spring, a new study from researchers at Virginia Commonwealth University Massey Cancer Center has uncovered a new connection between allergy and cancer that could potentially lead to therapies involving common antihistamines.
VCU welcomes new clinical research services executive director
Fredika A. Robertson, Ph.D., has joined Virginia Commonwealth University as its new executive director of Clinical Research Services (CRS) for the Center for Clinical and Translational Research (CCTR). She is also a professor in the Department of Internal Medicine in the VCU School of Medicine and a member of the Developmental Therapeutics research program at VCU Massey Cancer Center.
Massey on the Radio: Dr. Mark Malkin
Massey neuro-oncologist Mark G. Malkin, took to the airwaves recently to discuss his field and why he believes in the Massey difference.
Colorectal cancer is preventable and treatable
March is National Colorectal Cancer Awareness Month and, although the incidence rates for the disease have decreased, overall lifetime risk of developing colorectal cancer is 1 in 20, making it the third most common cancer in both men and women. The good news is that due to screening and treatment advances, colorectal cancer is one of the most preventable and treatable types of cancer. As a result, there are now more than 1 million colorectal cancer survivors in the United States.
Poklepovic presents at TEDxRVA
Andrew Poklepovic, M.D., oncologist and member of the Developmental Therapeutics research program at VCU Massey Cancer Center and assistant professor in the Division of Hematology, Oncology and Palliative Care at VCU School of Medicine, presents at this year’s TEDxRVA event. Dr. Poklepovic’s presentation, “Redefining the War on Cancer,” discusses targeted therapies, which target specific DNA mutations found to contribute to or help prevent the growth and development of cancer, and next generation immunotherapies, which are treatments that “reprogram” a person’s immune system cells so that they can better recognize and ultimately destroy cancer cells.